

any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Assistant Commissioner is authorized to deduct or credit said fees from or to Arnold, White & Durkee Deposit Account No. 01-2508/UTXC:538/HYL.

AMENDMENTS

In the claims:

Please cancel claim 46.

Please amend claim 29 as follows:

29. (Amended) A method for directly inhibiting HIV entry into a cell comprising the step of contacting said cell with a composition comprising a peptide of 8 to 24 residues comprising the sequence RAFVTIGK (SEQ ID NO:5), wherein said cell is in a human subject.

Please add the following new claim:

- 49. (New) A method for directly inhibiting HIV entry into a cell *in vitro* comprising the step of contacting said cell with a composition comprising a peptide of 8 to 24 residues comprising the sequence RAFVTIGK (SEQ ID NO:5). --

PENDING CLAIMS

29. (Amended) A method for directly inhibiting HIV entry into a cell comprising the step of contacting said cell with a composition comprising a peptide of 8 to 24 residues comprising the sequence RAFVTIGK (SEQ ID NO:5), wherein said cell is in a human subject.
30. The method of claim 29, wherein said peptide is 8 residues in length.
31. The method of claim 29, wherein said peptide is 15 residues in length.
32. The method of claim 31, wherein said peptide comprises the sequence RIQRGPGRAFVTIGK (SEQ ID NO:1).
33. The method of claim 29, wherein said peptide is 24 amino acids in length.
34. The method of claim 33, wherein said peptide comprises the sequence NNTRKSIRIQRGPGRAFVTIGKIG (SEQ ID NO:3).
35. The method of claim 29, wherein said peptide is in the form of a multimer.
36. The method of claim 35, wherein said multimer comprises a single chain comprising repeating units of said peptide.
37. The method of claim 36, wherein said repeating units are bonded through one or two cysteine residues.
38. The method of claim 35, wherein said multimer comprises a spacer peptide to which multiple copies of said peptide are bonded.
39. The method of claim 38, wherein said spacer peptide comprises glycyl residues to which each of said multiple copies of said peptide are bonded.
40. The method of claim 38, wherein said spacer peptide forms a surfactant-like micelle.
41. The method of claim 29, wherein said composition is dispersed in a pharmaceutically acceptable aqueous medium.
42. The method of claim 29, wherein said composition is administered at a dosage range of between about 10 micrograms to about 500 milligrams.
43. The method of claim 40, wherein dosage range is about 50 micrograms to about 1 milligram.
44. The method of claim 41, wherein said dosage range is about 100 micrograms.

45. The method of claim 29, further comprising contacting said cell with said composition a second time.
46. (Canceled) The method of claim 29, wherein said cell is in a human subject.
47. The method of claim 46, wherein said contacting comprises injection of said composition.
49. (New) A method for directly inhibiting HIV entry into a cell *in vitro* comprising the step of contacting said cell with a composition comprising a peptide of 8 to 24 residues comprising the sequence RAFVTIGK (SEQ ID NO:5).